These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 10658619

  • 1. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
    Elsworth JD, Taylor JR, Sladek JR, Collier TJ, Redmond DE, Roth RH.
    Neuroscience; 2000; 95(2):399-408. PubMed ID: 10658619
    [Abstract] [Full Text] [Related]

  • 2. Restoration of dopamine transporter density in the striatum of fetal ventral mesencephalon-grafted, but not sham-grafted, MPTP-treated parkinsonian monkeys.
    Elsworth JD, Brittan MS, Taylor JR, Sladek JR, al-Tikriti MS, Zea-Ponce Y, Innis RB, Redmond DE, Roth RH.
    Cell Transplant; 1996; 5(2):315-25. PubMed ID: 8689042
    [Abstract] [Full Text] [Related]

  • 3. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions.
    Elsworth JD, Deutch AY, Redmond DE, Taylor JR, Sladek JR, Roth RH.
    Neuroscience; 1989; 33(2):323-31. PubMed ID: 2622529
    [Abstract] [Full Text] [Related]

  • 4. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
    Albanese A, Granata R, Gregori B, Piccardi MP, Colosimo C, Tonali P.
    Neuroscience; 1993 Aug; 55(3):823-32. PubMed ID: 8105418
    [Abstract] [Full Text] [Related]

  • 5. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
    Kupsch A, Sautter J, Schwarz J, Riederer P, Gerlach M, Oertel WH.
    Brain Res; 1996 Nov 25; 741(1-2):185-96. PubMed ID: 9001722
    [Abstract] [Full Text] [Related]

  • 6. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration.
    Pérez-Otaño I, Oset C, Luquin MR, Herrero MT, Obeso JA, Del Río J.
    Neurosci Lett; 1994 Jul 04; 175(1-2):121-5. PubMed ID: 7970192
    [Abstract] [Full Text] [Related]

  • 7. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus).
    Taylor JR, Elsworth JD, Roth RH, Sladek JR, Redmond DE.
    Neuroscience; 1997 Dec 04; 81(3):745-55. PubMed ID: 9316026
    [Abstract] [Full Text] [Related]

  • 8. Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: an autoradiographic study.
    Elsworth JD, Brittan MS, Taylor JR, Sladek JR, Redmond DE, Innis RB, Zea-Ponce Y, Roth RH.
    Brain Res; 1998 Jun 08; 795(1-2):55-62. PubMed ID: 9622593
    [Abstract] [Full Text] [Related]

  • 9. MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys.
    Elsworth JD, Deutch AY, Redmond DE, Sladek JR, Roth RH.
    Brain Res; 1990 Apr 16; 513(2):320-4. PubMed ID: 2350702
    [Abstract] [Full Text] [Related]

  • 10. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease.
    Pifl C, Schingnitz G, Hornykiewicz O.
    Neurosci Lett; 1988 Oct 05; 92(2):228-33. PubMed ID: 3263594
    [Abstract] [Full Text] [Related]

  • 11. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.
    Pifl C, Schingnitz G, Hornykiewicz O.
    Neuroscience; 1991 Oct 05; 44(3):591-605. PubMed ID: 1754053
    [Abstract] [Full Text] [Related]

  • 12. MPTP-induced parkinsonism: acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment.
    Schneider JS.
    J Neurosci Res; 1992 Jan 05; 31(1):112-9. PubMed ID: 1613817
    [Abstract] [Full Text] [Related]

  • 13. Behavioral evaluation of hemiparkinsonian MPTP monkeys following dopamine pharmacological manipulation and adrenal co-graft transplantation.
    Howel LL, Byrd LD, McDonough AM, Iuvone PM, Bakay RA.
    Cell Transplant; 2000 Jan 05; 9(5):609-22. PubMed ID: 11144958
    [Abstract] [Full Text] [Related]

  • 14. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF.
    Elsworth JD, Deutch AY, Redmond DE, Sladek JR, Roth RH.
    Brain Res; 1987 Jul 14; 415(2):293-9. PubMed ID: 3496938
    [Abstract] [Full Text] [Related]

  • 15. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys.
    Alexander GM, Schwartzman RJ, Brainard L, Gordon SW, Grothusen JR.
    Brain Res; 1992 Aug 21; 588(2):261-9. PubMed ID: 1356591
    [Abstract] [Full Text] [Related]

  • 16. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE.
    J Neurosci; 2001 Sep 01; 21(17):6853-61. PubMed ID: 11517273
    [Abstract] [Full Text] [Related]

  • 17. Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys.
    Pifl C, Hornykiewicz O.
    Neurochem Int; 2006 Oct 01; 49(5):519-24. PubMed ID: 16698121
    [Abstract] [Full Text] [Related]

  • 18. Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin.
    Ueki A, Chong PN, Albanese A, Rose S, Chivers JK, Jenner P, Marsden CD.
    Neuropharmacology; 1989 Oct 01; 28(10):1089-97. PubMed ID: 2510050
    [Abstract] [Full Text] [Related]

  • 19. Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs.
    Wade TV, Schneider JS.
    J Neurosci; 2001 Jul 01; 21(13):4901-7. PubMed ID: 11425917
    [Abstract] [Full Text] [Related]

  • 20. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
    Oiwa Y, Eberling JL, Nagy D, Pivirotto P, Emborg ME, Bankiewicz KS.
    Front Biosci; 2003 Sep 01; 8():a155-66. PubMed ID: 12957824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.